This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

INS37217 Ophthalmic

Merck & Co., Inc.

Drug Names(s): denufosol tetrasodium

Description: INS37217 Ophthalmic has been shown in experimental models of retinal detachment to stimulate retinal re-attachment by reabsorbing (i.e., draining) extraneous sub-retinal fluid across the retinal pigment epithelium.

Deal Structure: INS37217 Ophthalmic was originally developed by Inspire.

In April 2011, Merck and Inspire Pharmaceuticals announced that they have entered into a definitive agreement under which Merck will acquire Inspire. In May 2011, Merck announced that it is has completed its acquisition of Inspire Pharmaceuticals.


INS37217 Ophthalmic News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug